Bristol-Myers Squibb And Pfizer Initiate New Study In The Apixaban Phase 3 Clinical Trial Program
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced the start of a new Phase 3 clinical trial to assess the effect of apixaban in patients with venous thromboembolism (VTE), a potentially fatal disease process that begins with blood clots in the leg veins or lungs.
New Meta-Analysis Confirms Safety Profile For NeoRecormon In Treating Anaemia In Cancer Patients
Data Published in the British Journal of Cancer Reports That NeoRecormon use has no Negative Impact on Overall Survival or Tumour Progression A new meta-analysis of all 12 prospective, randomised, controlled studies in 2, 301 cancer patients shows that treating anaemia with NeoRecormon(R) (epoetin beta) has no negative impact on survival, tumour progression or deaths caused by blood clots, when used within its approved indications (1).
The Prescribing Of Blood Thinning Drugs Can Be Carried Out Equally Safely By Computers And Medical Experts
The largest ever study into the administration of blood thinning drugs, principally Warfarin, has concluded that dosages calculated by computer are at least as safe and reliable as those provided by expert medical professionals..Increasing evidence of the value of these anticoagulant drugs in a wide range of clinical disorders such as abnormal heart rhythm, or atrial fibrillation, has led to a rapid rise in their use around the world.
Revolade reg; eltrombopag Data Presented At EHA: Updated Data For EXTEND Plus New Data For REPEAT And DELPHI Studies
GlaxoSmithKline announced data on the long-term safety and efficacy of its investigational drug Revolade (eltrombopag) for the treatment of chronic idiopathic thrombocytopenic purpura (ITP). [1] Results from the ongoing, open label EXTEND (Eltrombopag eXTENded Dosing) (Abstract 0949) study showed that 80% of patients achieved a platelet count of >50, 000/^A L at least once and 78% of these patients maintained platelets >50, 000/^A L for over 50% of their time in the study.
REVLIMID R Data For Newly Diagnosed Multiple Myeloma Reported At A Satellite Symposium During The 13th European Hematology Association Congress
Data from the ECOG E4A03 and SWOG 0232 studies were reported at a Satellite Symposium and showed that newly diagnosed multiple myeloma patients who are eligible for a transplant, obtain better outcomes when treated with REVLIMID (lenalidomide) plus dexamethasone.
Revolade reg; Eltrombopag Data Presented At EHA: Updated Data For Extend Plus New Data For Repeat And Delphi Studies
GlaxoSmithKline has announced data on the long-term safety and efficacy of its investigational drug Revolade (eltrombopag) for the treatment of chronic idiopathic thrombocytopenic purpura (ITP).1 Results from the ongoing, open label EXTEND (Eltrombopag eXTENded Dosing) (Abstract 0949) study showed that 80% of patients achieved a platelet count of >50, 000/^I 1/4 L at least once and 78% of these patients maintained platelets >50, 000/^I 1/4 L for over 50% of their time in the study.
Life-Saving Study Into Sepsis
Each year over a million people suffer from sepsis, a condition caused by an infection spreading through the body. If sepsis develops into severe sepsis then the death rate can rise to nearly 30 - 50%, equalling the number of deaths caused by a heart attack.
Soliris reg; Improved Fatigue Independent Of Changes In Anemia In Patients With PNH By Controlling Hemolysis
Soliris (eculizumab) therapy improved the often disabling fatigue experienced by patients with the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH) independent of improvements in anemia, according to data presented at the European Hematology Association (EHA) 13th Congress in Copenhagen.
ARYx Therapeutics Inc. Commences Phase 2 3 Clinical Trial On Oral Anticoagulant Agent ATI-5923
ARYx Therapeutics Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced it has commenced enrollment in a Phase 2/3 clinical trial comparing its oral anticoagulation therapy, ATI-5923, against the leading anticoagulant agent, warfarin. The purpose of the trial, named EmbraceAC, is to evaluate whether ATI-5923 is superior to warfarin in its ability to maintain patients within a target therapeutic range of the level of anticoagulation.
Doctors Underuse Effective Treatment For Sickle Cell Anemia
Uncertainties about proper use and possible long-term effects of hydroxyurea in the treatment of sickle cell anemia may be wrongly influencing doctors to avoid prescribing it to those in serious need, according to results of a literature review by specialists at Johns Hopkins.